HRS-9231

Phase 3Small molecule

SShanghai Shengdi Pharmaceutical Co., Ltd

HRS-9231 is one of 3 small molecule programs targeting Magnetic Resonance Imaging (MRI). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Magnetic Resonance Imaging (MRI)Completed

Magnetic Resonance Imaging (MRI)Phase 3

Completed

Competition

Competitive Landscape

2 competitors in Magnetic Resonance Imaging (MRI)

#DrugCompanyPhaseTrials

HRS-9231

SShanghai Shengdi Pharmaceutical Co., Ltd

Phase 3

2 2

Administration of Endorem

UUniversity of Edinburgh

Preclinical

2 3

Mantoux Test

UUniversity College, London

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Magnetic Resonance Imaging (MRI)2 trials

A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT06731829·78 enrolled

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase III Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Body Parts (Non-Central Nervous System) Magnetic Resonance Imaging (MRI)

Completed·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 3·NCT07275723·309 enrolled

Tolerance1 trial

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

Completed·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 1·NCT07123376·40 enrolled

Impaired Renal Function1 trial

Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function

Completed·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 1·NCT06657560·41 enrolled

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions1 trial

A Multicenter, Randomized, Double-Blind, Positive-Controlled, Cross-Over Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Completed·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 3·NCT07275814·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for HRS-9231. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HRS-9231 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HRS-9231. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Shengdi Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Shengdi Pharmaceutical Co., Ltd

HRS-9231

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Magnetic Resonance Imaging (MRI)2 trials

Tolerance1 trial

Impaired Renal Function1 trial

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions1 trial

References

Drug Info

Quick Facts

Related News